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Meta-analysis of probability estimates of worldwide
variation of CYP2D6 and CYP2C19
Anne B. Koopmans 1,2, Mario H. Braakman3,4, David J. Vinkers2, Hans W. Hoek 1,5,6 and Peter N. van Harten2,7
Abstract
Extensive migration has led to the necessity of knowledge regarding the treatment of migrants with different ethnical
backgrounds. This is especially relevant for pharmacological treatment, because of the significant variation between
migrant groups in their capacity to metabolize drugs. For psychiatric medications, CYP2D6 and CYP2C19 enzymes are
clinically relevant. The aim of this meta-analysis was to analyze studies reporting clinically useful information regarding
CYP2D6 and CYP2C19 genotype frequencies, across populations and ethnic groups worldwide. To that end, we
conducted a comprehensive meta-analysis using Embase, PubMed, Web of Science, and PsycINFO (>336,000 subjects,
318 reports). A non-normal metabolizer (non-NM) probability estimate was introduced as the equivalent of the sum-
prevalence of predicted poor, intermediate, and ultrarapid metabolizer CYP2D6 and CYP2C19 phenotypes. The
probability of having a CYP2D6 non-NM predicted phenotype was highest in Algeria (61%) and lowest in Gambia
(2.7%) while the probability for CYP2C19 was highest in India (80%) and lowest in countries in the Americas,
particularly Mexico (32%). The mean total probability estimates of having a non-NM predicted phenotype worldwide
were 36.4% and 61.9% for CYP2D6 and CYP2C19, respectively. We provide detailed tables and world maps
summarizing clinically relevant data regarding the prevalence of CYP2D6 and CYP2C19 predicted phenotypes and
demonstrating large inter-ethnic differences. Based on the documented probability estimates, pre-emptive
pharmacogenetic testing is encouraged for every patient who will undergo therapy with a drug(s) that is metabolized
by CYP2D6 and/or CYP2C19 pathways and should be considered in case of treatment resistance or serious side effects.
Introduction
Migration is a growing global phenomenon so that
Western-trained psychiatrists are increasingly treating
migrants with different cultural and ethnic back-
grounds1. In the psychopharmacological treatment of
migrants, variation in drug metabolism is an important
aspect that must be taken into account2. In psychiatry,
CYP2D6 and CYP2C19 are important drug-metabolizing
enzymes3–8. For example, drugs that are metabolized by
CYP2D6 include first- and second-generation anti-
psychotics, selective serotonin receptor inhibitors, and
tricyclic antidepressants6. Among those metabolized by
CYP2C19 are benzodiazepines, selective serotonin
receptor inhibitors, and tricyclic antidepressants6. Indi-
viduals’ genetic variation is the most important factor
influencing the kinetics of drug metabolism and thus
may contribute to intolerability-related discontinuation
or treatment failure9.
The outcome of a pharmacogenetic test (i.e., a patient’s
genotype, sometimes also referred to as diplotype) can be
translated into a predicted phenotype. A combination of
functional and non-functional alleles is responsible for the
activity of the enzymes. There are four phenotype groups:
poor (PM), intermediate (IM), normal (NM) (previously
referred to as “extensive”), and ultrarapid metabolizers
(UM), which are used to predict whether and how well a
drug is metabolized. The same drug dosage may lead to a
higher plasma level in PMs and IMs, compared to NMs,
because of slower drug clearance, while UMs may have
lower plasma levels than NMs because of a higher rate of
drug clearance. Plasma levels are often related to the
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efficacy of a drug and the risk of dose-related side effects,
with more severe side effects found in PMs and IMs than
in NMs10–15.
The prevalence of CYP polymorphisms also varies
considerably across ethnic groups and plays a major role
in inter-individual and inter-ethnic differences in drug
metabolism and response16. For example, in European
populations, just 2–3% of the population have a CYP2D6
UM profile, compared to 20–29% in East-African popu-
lations17,18. In contrast, CYP2C19 PMs are considerably
more frequent in Asians (~12%) than in Europeans
(~2%)19. Some allelic variants such as CYP2D6*40 and *45
are only seen in specific populations20,21.
The Clinical Pharmacogenetics Implementation Con-
sortium (CPIC) has published guidelines with recom-
mendations for drug choice and dosage based on
phenotype predictions22–25.
Other groups, including the Royal Dutch Association for
the Advancement of Pharmacy—Pharmacogenetics Work-
ing Group, have also published guidelines (information for
both organizations is available through the Pharmacoge-
nomics Knowledge Base at https://www.pharmgkb.org/
guidelines). CYP2D6 and CYP2C19 allele frequency infor-
mation has been compiled by CPIC and is available at
https://www.pharmgkb.org/page/cyp2d6RefMaterials. Gae-
digk et al., Fricke-Galindo et al., and Llerena et al. have
described CYP2D6 and CYP2C19 phenotype prediction
from genotype across world populations17,19,26.
Although there is a wealth of information, pharmacoge-
netics is still not being widely used in clinical practice.
Several studies have shown the relationship between CYP
activity, blood serum levels, and side effects, but there have
been few studies on clinical effectivity. Most of the studies
are cross-sectional and observational, while prospective
studies are often underpowered4,27–29. For some drugs,
clinicians are used to working with therapeutic drug
monitoring and they may prefer this over genotyping.
Another reason is the lack of education of practitioners
on this topic and the belief that pharmacogenetics “is not
ready” for use in daily clinical practice30–33. Despite these
barriers, pharmacogenetics is increasingly being adopted
by major health centers, and the body of literature in
support of pharmacogenetic testing is growing27,29,34–39.
The aim of our meta-analysis was to assess studies
reporting clinically useful information about CYP2D6 and
CYP2C19 genotype frequencies across populations and
ethnic groups worldwide. We introduce the concept of
the non-normal metabolizer (non-NM) probability esti-
mate, for which we calculated the sum-prevalence of a
population for having a poor, intermediate, or ultrarapid
CYP2D6 or CYP2C19 predicted phenotype. The sum-
prevalence of these three predicted phenotypes presents a
single measurement for non-normal metabolism in the
populations of interest. It is defined as the equivalent of
the prevalence of PM+ IM+UM predicted phenotypes
of the enzyme in percentages.
Methods
For this study, we followed the checklist in the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
statement40,41. The protocol for the current systematic
review was not registered prior to the review.
Review of literature
We conducted a literature review using the Embase,
PubMed, Web of Science, and PsycINFO databases
(1990–2019). The terms “CYP2D6” AND/OR “CYP2C19”
AND “prevalence” OR “ethnicity” OR “race” AND “heal-
thy subject” OR “normal control,” and variations on these
terms and the names of different countries and continents
were used in all fields. The last search was conducted on
July 3, 2019.
Our inclusion criteria were: (1) CYP2D6 or CYP2C19
allele frequencies from original data were reported; (2) the
evaluated subjects did not have a specific disease (controls
from case–control studies were included); (3) ethnicity
was reported; (4) the article was published in English; (5) a
minimum of 20 participants was investigated. If only an
abstract was available, the article was included if all the
above information was available; and (6) in order to be
able to calculate a probability estimate, it was necessary to
assess a minimum number of non-functional alleles and
alleles with decreased function as well as a number of
gene duplications. The genotyping assay included at least
the following allelic variants: CYP2C19*2 and *17 in
Africans, Americans, Europeans, Middle Easterners,
Central/South East-Asians and African Americans;
CYP2C19*2, *3, and *17 in Oceanians and CYP2C19*2
and *3 in East Asians; CYP2D6*2, *5, *17, *29, and *41 in
Africans; CYP2D6*2 and *4 in Americans; CYP2D6*2 and
*10 in East Asians; CYP2D6*2, *4, and *41 in Europeans;
CYP2D6*2, *4, *10, and *41 in Middle Easterners and
Central/South East-Asians; CYP2D6*5 in Oceanians; and
CYP2D6*2, *4, *17, and *29 in African Americans.
An eligibility assessment was performed independently
in a standardized manner by A.B.K. and D.J.V. The first
screening was based on the article abstracts; the next
selection was based on the full text. Disagreements
between the two reviewers were resolved by discussion to
reach a consensus.
Data extraction
The data were independently extracted from the studies
by two investigators (A.B.K. and P.B.) and randomly
checked by two investigators (D.J.V. and A.B.K.). For some
studies, authors were contacted for clarification of the data.
Information was extracted from each study as follows:
(1) ethnicity of the participants; (2) definition of ethnicity
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(self-reported or genetic ancestry); (3) country of the
studied population; (4) number of study participants; (5)
study design (prevalence study, case–control study,
experimental study); (6) allele frequencies; (7) diplotype
frequencies; (8) predicted phenotype frequencies.
Star (*) alleles were assigned according to the Pharma-
cogenetic Variation (PharmVar) Consortium at Pharm-
Var.org42,43.
Ethnicity and geographical regions
To be able to compare outcomes with previous meta-
analyses, reported ethnicity was assigned to geographic
regions, as done in previous meta-analysis about this sub-
ject, according to the Human Genome Diversity Project44.
Seven major regions were considered: Africa, Americas
(including Latino Americans and indigenous inhabitants of
North America and Canada), East Asia, Europe (including
North Americans and Canadians), the Middle East, Ocea-
nia, and Central/Southeast Asia; with one exception,
namely, that African Americans were listed separately from
Africans17. Here the frequencies of PM, IM, normal
metabolizer (NM), and UM are reported by ethnicity,
whereas the probability estimates of being a non-NM are
reported by country. In many studies, these two factors—
country and ethnicity—overlap, but for some studies we
had to assign an ethnicity to a country to be able to show
the information in world maps (i.e., the two factors were
not distinguished). The origin of the investigated ethnicity
determined the country and region to which a population
was assigned. An exception was made for Latin America, in
which the population is an admixture of multiple origins
(e.g., European, African, Asian, and Amerindian) and no
clear lineages can be determined; they were all considered
as populations of the Americas and determined as
belonging to the country they live in45,46. For some ethni-
cities, we could not determine a country of origin (for
example, East Asians or Europeans) so we have indicated
them as “missing” in the figures.
Translation of genotype into phenotype
For each geographical region, the mean frequency of
alleles was determined. In order to predict CYP2D6 and
CYP2C19 phenotype frequencies from genotype data, we
applied the activity score (AS) system to both genes (the
AS system is widely used for CYP2D6 and was adapted to
CYP2C19 to facilitate the translation process)47. Briefly, a
normal function allele was valued as 1, decreased function
alleles as 0.25 or 0.5, a non-functional allele as 0, and
increased function allele as 1.5. Gene duplications
received double the value of their singleton counterparts.
Homozygous carriers of non-functional alleles were
classified as PMs (AS= 0). Carriers with one functional or
decreased function allele and one non-functional allele
and those carrying two decreased function alleles were
classified as IMs (AS= 0.25–1)47. Homozygous carriers of
normal function alleles and heterozygous carriers with
one decreased function and one normal function allele
were classified as NMs (AS= 1.25–2.25)47. Carriers of one
or more increased function alleles and carriers of a
duplication or multiplication of a functional allele were
classified as UMs (AS > 2.25)47 (https://cpicpgx.org/
resources/term-standardization/). CYP2C19 rapid and
ultrarapid metabolizers were pooled and analyzed as
UMs. The functionality of the CYP2D6 and CYP2C19
alleles was classified as listed by PharmVar in Table 1.
In this meta-analysis, we applied strict criteria. To max-
imize the accuracy of the frequencies of the predicted phe-
notypes, we only predicted a phenotype if the original
publication reported a minimum of non-/decreased function
alleles and the assays included tests for gene duplications.
Since the prevalence of alleles differed greatly per region, we
used criteria specific for each geographical region. Alleles
more prevalent than 0.05 (5%) in the major region (Table 2)
had to be investigated in the countries within that region to
be included in the phenotype predictions.
Calculations and statistics
All analyses were performed with IBM SPSS Statistics
Version 25. If only diplotypes were reported, single allele
frequencies were calculated. If only single allele frequencies
were reported, diplotype frequencies were calculated using
the Hardy–Weinberg equilibrium (p2+ 2pq+ q2= 1). For
studies that did not report the prevalence of CYP2D6*1, the
allele frequency was calculated as 100% minus the sum of
variants17. The diplotypes were translated into predicted
phenotypes according to the CPIC.
We introduce here the concept of the non-NM probability
estimate. It is defined as the sum of the prevalence of PM+
IM+UM predicted phenotypes of the enzymes CYP2D6 or
CYP2C19 in percentages. Thus it is equivalent to the pre-
valence (as percentage) of all the non-normal phenotypes in
a population. We use the term probability estimate exclu-
sively in this sense and it is in fact a proportion of the
Table 1 Functionality of CYP2D6 and CYP2C19 alleles
(https://www.pharmvar.org/gene).
CYP2D6 CYP2C19
0 *3–*8, *15, *18, *31, *36, *47, *51,
*56, *57, *62, *92, *100, and *101
*2, *3, *4, *5, *6, *7, *8,
*23, and *24
0.25–0.5 *9, *10, *17, *29, *41, *49, *50, *54,
*55, *59, and *72
*9, *10, *12, *16, *25
and *27
1 *1, *2, *27, *39, *45, *46, and *48 *1, *13, *15 and *18
1.5 *53 *17
Unknown *43, *60, *65, *82, *84, *85, and *86
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possible outcomes in a population. It is equal to 100% minus
the percentage of NM in a given population.
The studies were weighted by sample size (number of
participants) when we calculated the mean predicted
phenotypes per country and ethnicity.
Results
Of the 2873 publications retrieved from the database,
318 original research papers met our inclusion criteria
(Fig. 1). The analyses of CYP2D6 (n= 200 papers) and
CYP2C19 (n= 159 papers) included 261,296 and 257,745
healthy individuals. The alleles most frequently investi-
gated were CYP2D6*1–*6, *10, *17, and CYP2C19*1–*3.
Allele frequencies are shown per major geographical
region in Table 2 (for references, please see Supplemental
Table 1). The most frequently observed variant alleles
across all subjects were CYP2D6*2, *4, *10, and *41 and
CYP2C19*2 and *17. As expected, allele frequencies varied
substantially among ethnicities and countries. We found
89 studies that reported on more than one ethnic group.
Overall, African and Middle Eastern countries were
underrepresented, while European populations were the
most frequently investigated.
CYP2D6
Prevalence of predicted phenotypes by ethnicity
Predicted phenotype was reported or could be inferred
from 51 studies for 116 ethnicities, covering n= 194,714
individuals. These studies were selected for fulfilling the
minimum number of alleles tested as prescribed by our
region-specific criteria. Due to the high frequency of allele
duplications, high percentages of CYP2D6 UM were
found in the Mozabite people, a Berber ethnic group in
the Sahara, North Africa (39.5%)48, in non-Austronesian
Melanesians (21.5%)48, and in the ethno-religious Druze
from the Middle East (21.4%)48. High percentages of
CYP2D6 PM were found in Europeans, for example, in
the British (12.1%)49, the Danish (10.6%)50, and Basque
(French) people (9.7%)48 due to the high frequency of
CYP2D6*4. Frequencies of CYP2D6 predicted phenotypes
by ethnicity are summarized in Table 3 (for references,
please see Supplemental Table 2).
Probability estimates by country
The probability of having a CYP2D6 non-NM predicted
phenotype is the highest in Algeria (non-NM probability
estimated to be 61.2%; *4, *17, *41, and duplications)48,
Argentina (non-NM probability estimate 51.4%; *4, *41,
and duplications)51, and France (non-NM probability
estimate 50.4%; *4, *5, *41, and duplications)48. The
CYP2D6 non-NM probability estimate was lowest in
several populations from Africa (Gambia 2.7%, Kenya
4.0%, and Sierra Leone 5.9%) and South-East Asia (Viet-
nam 5.1%, Sri Lanka 7.8%)49. See Fig. 2 for CYP2D6 non-
NM probability estimates and Fig. 3 for CYP2D6 non-NM
probability estimates plotted on a world map.
Fig. 1 PRISMA flow diagram of the studies included in the analyses. n= number of studies.
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Table 3 Mean frequencies of CYP2D6 predicted phenotypes per ethnicitya.
Ethnicity Othersb
n M SD M SD M SD M SD M
Africa
000.0000.0950.0000.0825.0000.0493.0000.0820.03025nacirfA
African (North and East) 65 0.017 0.000 0.195 0.000 0.346 0.000 0.069 0.000 0.373
Biaka, Pygmies (Subsaharan Africa) 36 0.002 0.000 0.141 0.000 0.802 0.000 0.000 0.000 0.055
Colored (South African) 199 0.020 0.010 0.440 0.010 0.492 0.002 0.017 0.009 0.031
180.0000.0000.0000.0897.0000.0111.0000.0010.099)nairegiN(nasE
160.0000.0000.0000.0219.0000.0810.0000.0900.0311naibmaG
Luhya in Webuye (Kenian) 99 0.000 0.000 0.040 0.000 0.848 0.000 0.000 0.000 0.112
Mandenka (Subsaharan Africa) 24 0.035 0.000 0.471 0.000 0.446 0.000 0.000 0.000 0.047





Xhosa (South African) 53 0.038 0.000 0.363 0.000 0.480 0.000 0.038 0.000 0.081
Yoruba (Nigerian) (Ibadan) 108 0.000 0.000 0.046 0.000 0.898 0.000 0.000 0.000 0.056
Yoruba (Subsaharan Africa) 25 0.032 0.000 0.338 0.000 0.565 0.000 0.064 0.000 0.000
240.0410.0920.0790.0365.0701.0143.0600.0420.0344naciremAnacirfA
Americas
Admixed Latin Americans 8246 0.033 0.006 0.303 0.031 0.672 0.006 0.023 0.023 0.000
African Caribbean (Barbados) 96 0.021 0.000 0.063 0.000 0.854 0.000 0.000 0.000 0.062
African Caribbean from Barbados 
590.0000.0970.0000.0645.0000.0762.0000.0210.0301)aciRatsoC(
Afro-Latin Americans 93 0.022 0.000 0.258 0.000 0.645 0.000 0.075 0.000 0.000
720.0000.0110.0000.0278.0000.0230.0000.0950.0781naidnInaciremA
Brazilian (North East) 261 0.025 0.000 0.281 0.000 0.627 0.000 0.019 0.000 0.047
150.0000.0620.0000.0946.0000.0352.0000.0120.0642)htroN(nailizarB
Brazilian (South East) 258 0.020 0.000 0.271 0.000 0.640 0.000 0.023 0.000 0.045
940.0000.0310.0000.0236.0000.0182.0000.0420.0552)htuoS(nailizarB
Brazilian from African descent 92 0.017 0.000 0.320 0.000 0.625 0.000 0.029 0.000 0.008
Brazilian from European descent 87 0.030 0.000 0.288 0.000 0.585 0.000 0.077 0.000 0.020
Central Native Americans 196 0.102 0.000 0.342 0.000 0.520 0.000 0.036 0.000 0.000
060.0800.0010.0001.0476.0651.0912.0500.0730.0512naibmoloC
000.0000.0680.0000.0468.0000.0940.0000.0000.018)nacixeM(saroC
Cuban from European descent 130 0.023 0.000 0.292 0.000 0.623 0.000 0.062 0.000 0.000
000.0000.0620.0000.0316.0000.0523.0000.0340.0233naebbiraChctuD
900.0420.0430.0400.0037.0440.0502.0210.0120.0752nairodaucE
Huicholes (Mexican) 107 0.000 0.000 0.150 0.000 0.645 0.000 0.206 0.000 0.000
000.0000.0050.0000.0365.0000.0143.0000.0740.00351snairebI
130.0000.0520.0000.0226.0000.0892.0000.0520.0761dadinirT-odnI
Karitiana (South American) 24 0.000 0.000 0.000 0.000 0.837 0.000 0.159 0.000 0.004
Lacandones (Mexican) 154 0.000 0.000 0.214 0.000 0.758 0.000 0.025 0.000 0.003
320.0000.0281.0000.0195.0000.0502.0000.0000.044)nacixeM(ayaM





North Native Americans 956 0.003 0.000 0.129 0.000 0.773 0.000 0.095 0.000 0.000
280.0000.0000.0000.0819.0000.0000.0000.0000.058naivureP
Pima (South American) 25 0.006 0.000 0.134 0.000 0.718 0.000 0.141 0.000 0.000
511.0000.0000.0000.0977.0000.0840.0000.0850.0401naciRotreuP
000.0000.0040.0000.0027.0000.0002.0000.0040.052naciremAhtuoS
South Native Americans 214 0.000 0.000 0.126 0.000 0.869 0.000 0.005 0.000 0.000
Surui (South American) 21 0.000 0.000 0.000 0.000 1.000 0.000 0.000 0.000 0.000
Tarahumares (Mexican) 74 0.014 0.000 0.257 0.000 0.622 0.000 0.122 0.000 0.000
Tepehuanos (Mexican) 129 0.000 0.000 0.015 0.000 0.931 0.000 0.054 0.000 0.000
White Latin Americans 282 0.032 0.000 0.302 0.000 0.599 0.000 0.067 0.000 0.000
Central/ South East Asia
Balochi (Central/South Asia) 25 0.010 0.000 0.216 0.000 0.738 0.000 0.036 0.000 0.000
530.0000.0000.0000.0488.0000.0850.0000.0320.068ilagneB
Brahui (Central/South Asia) 25 0.010 0.000 0.206 0.000 0.784 0.000 0.000 0.000 0.000
Burusho (Central/South Asia) 25 0.010 0.000 0.190 0.000 0.800 0.000 0.000 0.000 0.000
010.0000.0000.0000.0159.0000.0920.0000.0010.0301)naidnI(itarajuG
Hazara (Central/South Asia) 25 0.032 0.000 0.295 0.000 0.608 0.000 0.064 0.000 0.000
Kalash (Central/South Asia) 25 0.006 0.000 0.151 0.000 0.843 0.000 0.000 0.000 0.000
Makrani (Central/South Asia) 25 0.020 0.000 0.260 0.000 0.720 0.000 0.000 0.000 0.000
Pathan (Central/South Asia) 25 0.010 0.000 0.202 0.000 0.753 0.000 0.036 0.000 0.000
110.0000.0000.0000.0609.0000.0370.0000.0010.069)naidnI(ibajnuP





Uyghurs (Central/South Asia) 25 0.010 0.000 0.220 0.000 0.770 0.000 0.000 0.000 0.000
Viet Kinh (Vietnamese) 99 0.000 0.000 0.051 0.000 0.949 0.000 0.000 0.000 0.001
000.0000.0830.0000.0496.0000.0152.0000.0610.0051aidnInretseW
MUMNMIMP
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CYP2C19
Prevalence of predicted phenotypes by ethnicity
Data were retrieved from 73 studies describing
225,173 subjects of 85 ethnic groups/countries. These
studies were selected for fulfilling the minimum number of
alleles tested as prescribed by our region-specific criteria.
The UM predicted phenotype is rather common in Ecua-
dorian Mestizos (41.4%)52, Dargins (39.8%)53, and ethnic
groups living in the North Caucasus in Russia and in
Burushu, Pakistan (39.0%)54,55 owing to a high prevalence
of >20% of CYP2C19*17 in all these populations. High
percentages of CYP2C19 PMs were found in Indian and
Pakistani populations (Naik 31.0%56 and Saraiki 20.0%55),
Tohoku Japanese (18.9%)57, and in Chinese Hui
(28.0%)58,59 due to the presence of the CYP2C19*2 and *3
non-functional alleles. Table 4 summarizes the frequencies
of CYP2C19 predicted phenotypes by ethnicity (for refer-
ences, please see Supplemental Table 3).
Probability estimates by country
The probability of having a CYP2C19 non-NM pre-
dicted phenotype due to high frequencies of the non-
functional CYP2C19*2 allele and/or the increased func-
tion CYP2C19*17 allele is highest in India (non-NM
probability estimate 80.1%)56,60,61, Pakistan (non-NM







































Arabian Bedouins (Israel) 50 0.020 0.000 0.220 0.000 0.720 0.000 0.040 0.000 0.000
Bedouin (Middle Eastern) 49 0.013 0.000 0.245 0.000 0.590 0.000 0.049 0.000 0.103
Druze (Middle Eastern) 48 0.018 0.000 0.225 0.000 0.536 0.000 0.214 0.000 0.006
000.0740.0711.0390.0504.0550.0244.0240.0630.0111)learsI(hsiweJ
Palestinian (Westbank) 51 0.012 0.000 0.209 0.000 0.683 0.000 0.084 0.000 0.012
Oceania
Aboriginal (North West Australia) 239 0.004 0.000 0.180 0.000 0.816 0.000 0.000 0.000 0.000
non-Austronesian Melanesian 22 0.000 0.000 0.002 0.000 0.781 0.000 0.215 0.000 0.002
Total 194714 0.049 0.018 0.287 0.149 0.644 0.154 0.028 0.019 0.000
M mean, n number of genotyped subjects, SD standard deviation, PM poor metabolizers, IM intermediate metabolizers, NM normal metabolizers, UM ultrarapid
metabolizers.
aFor references, please see Supplemental Table 2.
bAn SNP combination that could not be assigned to a known allele/phenotype.
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probability estimate 69.2%)64,65. The probability is lowest
in countries in the Americas, particularly Mexico (non-
NM probability estimate 31.7%)66–68 and Costa Rica (non-
NM probability estimate 33.9%)69. CYP2C19 non-NM
probability estimates are shown in Fig. 4, and Fig. 5 dis-
plays CYP2C19 non-NM probability estimates on a world
map.
Discussion
In this meta-analysis, we introduce a clinical useful
concept of a non-NM probability estimate as the equiva-
lent of the sum-prevalence (in percentages) of PM+ IM+
UM predicted CYP2D6 and CYP2C19 phenotypes. The
mean totals of non-NM probability estimates worldwide
were 36.4% (CYP2D6) and 61.9% (CYP2C19). This means
that more than half of all psychiatric patients have a non-
normal predicted CYP2D6 and/or CYP2C19 metabolizer
phenotype. Since >75% of the psychopharmacological
drugs are metabolized by one or both of these enzymes6,70,
the results of our meta-analysis emphasize the importance
of integrating pharmacogenetic information into clinical
practice, especially when treating patients who have had
adverse drug events or show treatment resistance.
We included a total of 318 studies in our meta-analysis
of CYP2D6 and CYP2C19 genotypes in healthy popula-
tions of which genotype requirements were fulfilled by
118 studies (37%). This is an important requirement,
because having too few CYP2D6 or CYP2C19 alleles in a
study may not accurately determine predicted phenotype
from genotype data.
Diversity within major regions
Although grouping populations can simplify reporting
of pharmacogenetic alleles, we grouped ethnicities within
geographical regions to enable comparisons with other
published meta-analyses71,72. The prevalences of our
CYP2D6 predicted phenotypes were in general agreement
with those reported by Gaedigk et al.17. However, our data
predicted a higher percentage of UMs for Africans (i.e.,
5.5%, n= 562 versus 3.8%, n= 430). This difference may
be explained by the fact that we weighted the number of
genotyped subjects when calculating the mean allele fre-
quencies for our meta-analysis. In Gaedigk et al.’s report,
studies were not weighted by sample size, so small studies
might have had a bigger influence on the mean. We also
included two studies in Africans that were not included by
Fig. 2 CYP2D6 non-normal probability estimate per country. Country (genotyped subjects); non-normal probability estimate in percentage.
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Gaedigk et al. due to their small sample size and thus not
meeting their requirements of at least 50 study subjects;
they both reported higher frequencies of UMs48,73. In
contrast, in the South Central Asian population the per-
centage of UMs found by Gaedigk et al. was higher than
those reported here, 2.8% (n= 370) vs. 2.1% (n= 434),
due to the inclusion of two studies in South East Asians in
this meta-analysis, which found no UMs73,74.
In contrast with Fricke-Galindo et al.19 and the CPIC’s
CYP2C19 allele frequency table (https://www.pharmgkb.
org/page/cyp2c19RefMaterials), we found a much higher
prevalence of 25.0% for CYP2C19 UMs in Oceania (vs. 0%
and 1.5%). This is because we only included studies
investigating the CYP2C19*17 increased function allele,
which leads to rapid and ultrarapid metabolizer predicted
phenotypes. Studies that do not investigate this allele yield
underestimates of the prevalence of UMs.
Clinical practice
Some issues need to be addressed in translating geno-
type data to information useful for clinical practice.
Although prevalences of non-NM are high, there is no
conclusive evidence whether CYP genotyping is beneficial
for clinical outcomes in psychiatric practice. There are a
few prospective studies analyzing the clinical utility of
CYP genotyping and they report contradictory outcomes
in diverse populations27–29. So far, it is still unclear which
patient groups might benefit from genotyping and see
better treatment outcomes. One reason for the uncer-
tainty is the possibility of the transformation of genotypic
EMs into phenotypic PMs by multiple causes, for exam-
ple, due to smoking, CYP2D6 and CYP2C19 inhibiting
medication (e.g., bupropion and esomeprazole), CYP2D6
and CYP2C19 inducing medication (e.g., oritavancin and
carbamazepine), and inflammation or co-morbidities75,76.
This phenomenon is called phenoconversion: it has been
described in diverse populations77–79. If this is happening
on a large scale, it means genotypic outcomes could be
unreliable for use in clinical practice. It may already
influence outcomes of studies on the effectivity of CYP
genotyping in clinical practice28. Another issue may arise
with genotyping patients who have been on treatment for
several years, because their brain has adapted to the
changed levels of neurotransmitters and the side effects
are no longer reversible80,81.
Lastly, the category of the IM has been the subject of
debate82. In this meta-analysis, we categorized the IM as
defined by the CPIC47. Because IMs only show minor
differences in metabolism from NMs83, one could cate-
gorize them in the NM group. However, other studies
have indicated that IMs show lower oral drug clearance,
higher blood serum levels, and have higher chances of side
Fig. 3 Worldwide CYP2D6 non-normal metabolizer probability estimates.
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Table 4 Mean frequencies of CYP2C19 predicted phenotypes per ethnicitya.
Ethnicity Othersb
n M SD M SD M SD M SD M
Africa
African 5203 0.033 0.000 0.310 0.000 0.344 0.000 0.335 0.000 0.000
Cape Mixed Ancestry 
(South African) 75 0.080 0.000 0.400 0.000 0.350 0.000 0.170 0.000 0.000
Tzotziles (Ugandese) 99 0.020 0.000 0.230 0.000 0.510 0.000 0.240 0.000 0.000
Xhosa (South African) 100 0.030 0.000 0.490 0.000 0.390 0.000 0.090 0.000 0.000
African American 3533 0.039 0.007 0.308 0.001 0.337 0.013 0.316 0.020 0.001
Americas
Admixed Latin Americans 5789 0.011 0.000 0.192 0.000 0.661 0.000 0.210 0.000 0.000
African Caribbeans from 
Barbados (Costa Rica) 46 0.000 0.000 0.315 0.000 0.345 0.000 0.326 0.000 0.014
Brazilian 1043 0.018 0.000 0.230 0.000 0.482 0.000 0.270 0.000 0.000
Bribri (Costa Rican) 23 0.000 0.000 0.082 0.000 0.834 0.000 0.087 0.000 0.000
Costa Rican 36 0.000 0.000 0.219 0.000 0.717 0.000 0.056 0.000 0.008
Dutch Caribbean 332 0.041 0.000 0.241 0.000 0.372 0.000 0.345 0.000 0.001
Ecuadorian 139 0.008 0.000 0.243 0.000 0.591 0.000 0.159 0.000 0.000
Guarani (Brazil) 90 0.012 0.000 0.197 0.000 0.771 0.000 0.019 0.000 0.000
Guaymi (Costa Rican) 24 0.000 0.000 0.000 0.000 0.960 0.000 0.040 0.000 0.000
Mestizo (Costa Rican) 141 0.000 0.000 0.144 0.000 0.671 0.000 0.177 0.000 0.008
Mestizo (Ecuadorian) 297 0.007 0.000 0.151 0.000 0.428 0.000 0.414 0.000 0.000
Mestizo (Mexican) 300 0.000 0.000 0.170 0.000 0.660 0.000 0.170 0.000 0.000
Mexican 568 0.014 0.007 0.208 0.007 0.696 0.070 0.082 0.084 0.000
Central/ South East Asia
Buruhi (Pakistani) 118 0.060 0.000 0.600 0.000 0.200 0.000 0.140 0.000 0.000
Burushu (Pakistani) 28 0.000 0.000 0.150 0.000 0.460 0.000 0.390 0.000 0.000
Hazara (Pakistani) 102 0.000 0.000 0.410 0.000 0.270 0.000 0.320 0.000 0.000
Indian (West) 102 0.123 0.000 0.455 0.000 0.299 0.000 0.123 0.000 0.000
Kalash (Pakistani) 64 0.050 0.000 0.560 0.000 0.280 0.000 0.110 0.000 0.000
Koya (Indian) 460 0.152 0.000 0.499 0.000 0.150 0.000 0.197 0.000 0.003
Naik (Indian) 100 0.310 0.000 0.450 0.000 0.130 0.000 0.110 0.000 0.000
Pakistani 685 0.121 0.013 0.452 0.014 0.184 0.047 0.243 0.020 0.000
Parsi (Pakistani) 90 0.000 0.000 0.320 0.000 0.300 0.000 0.380 0.000 0.000
Pathan (Pakistani) 170 0.070 0.000 0.460 0.000 0.320 0.000 0.150 0.000 0.000
Punjabi (Pakistani) 218 0.070 0.000 0.460 0.000 0.280 0.000 0.190 0.000 0.000
Saraiki (Pakistani) 59 0.200 0.000 0.400 0.000 0.300 0.000 0.100 0.000 0.000
Sindhi (Pakistani) 179 0.089 0.000 0.453 0.000 0.352 0.000 0.106 0.000 0.000
South Asian 8256 0.118 0.000 0.458 0.000 0.280 0.000 0.162 0.000 0.000
Tamil (Indian) (South) 206 0.184 0.000 0.310 0.000 0.288 0.000 0.219 0.000 0.000
East Asia
Bai (Chinese) 202 0.095 0.000 0.425 0.000 0.473 0.000 0.000 0.000 0.006
Chinese 754 0.127 0.025 0.463 0.008 0.410 0.016 0.001 0.003 0.000
East Asian 5407 0.142 0.013 0.463 0.019 0.380 0.013 0.021 0.011 0.000
Hakka (Chinese) 6686 0.131 0.000 0.452 0.000 0.417 0.000 0.000 0.000 0.000
Han (Chinese) 1972 0.144 0.043 0.437 0.038 0.416 0.064 0.002 0.009 0.002
Han (Chinese) (North) 1000 0.137 0.000 0.488 0.000 0.373 0.000 0.000 0.000 0.002
Han (Chinese) (South) 1127 0.146 0.000 0.502 0.000 0.349 0.000 0.000 0.000 0.003
Han (Taiwanese) 180 0.118 0.000 0.516 0.000 0.365 0.000 0.000 0.000 0.001
Hui (Chinese) 265 0.280 0.023 0.441 0.070 0.279 0.093 0.000 0.000 0.000
Japanese 2577 0.175 0.038 0.488 0.038 0.333 0.040 0.003 0.005 0.001
Kazakh (Chinese) 107 0.075 0.000 0.318 0.000 0.607 0.000 0.000 0.000 0.000
Li (Chinese) 265 0.117 0.039 0.439 0.043 0.443 0.081 0.000 0.000 0.000
Mongolian 553 0.123 0.056 0.427 0.047 0.450 0.099 0.000 0.000 0.000
Shanghai (Chinese) 96 0.135 0.000 0.385 0.000 0.469 0.000 0.000 0.000 0.011
Shantou (Chinese) 96 0.073 0.000 0.365 0.000 0.510 0.000 0.021 0.000 0.031
Shenyang (Chinese) 96 0.042 0.000 0.327 0.000 0.598 0.000 0.033 0.000 0.000
South Korean 1962 0.131 0.020 0.474 0.030 0.391 0.030 0.003 0.007 0.000
Tibetan Chinese 96 0.041 0.000 0.406 0.000 0.563 0.000 0.031 0.000 0.000
Tohoku (Japanese) 57 0.189 0.000 0.575 0.000 0.213 0.000 0.000 0.000 0.023
Uyghurs (Chinese) 459 0.095 0.035 0.382 0.070 0.530 0.105 0.000 0.000 0.000
Xi’an (Chinese) 96 0.146 0.000 0.313 0.000 0.521 0.000 0.010 0.000 0.010
PM IM NM UM
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effects than NMs84–86. For this reason, we consider that
the IM status is clinically relevant for psychiatric patients
and guidelines for some medications are now advising
dose adjustments for this predicted phenotype25,87. Esti-
mations of the worldwide prevalence of only PM+UM
were 7.75% (CYP2D6) and 32.94% (CYP2C19) (Supple-
mental Figs. 1 and 2).
Strengths and limitations
We included studies with a small number of partici-
pants (n ≥ 20), as well as controls from case–control stu-
dies, which increased the number of studies we could
include. Bias was minimized by excluding studies of
populations diagnosed with a disease to prevent con-
founding our data (i.e., disease associations with specific
allele frequencies88–94). On the other hand, some large
studies had to be excluded due to their inclusion of non-
healthy individuals, which might have biased the out-
comes of some countries95.
Another strength is that we used region-specific
inclusion criteria to maximize the accuracy of the phe-
notype predictions17,19,26. This helped to avoid applying
criteria based on studies in Western countries to other
regions of the world. This led to the exclusion of studies
reporting on too few allelic variants and of studies
focusing on the determination of only PM or UM in a
population18,96,97.
Studies reporting allele frequencies of merely
CYP2C19*2 and *3 or studies investigating CYP2D6 allele
duplications, but with no minimum set of variants, are
certainly of scientific importance but not of practical
importance for clinicians because no complete risk
inventory of the metabolizer phenotype could be deter-
mined. Because we excluded studies not investigating
Table 4 continued
Europe
Avars (Russian) 90 0.016 0.000 0.222 0.000 0.453 0.000 0.309 0.000 0.000
Danish 276 0.022 0.000 0.258 0.000 0.442 0.000 0.279 0.000 0.000
Dargins (Russian) 50 0.003 0.000 0.095 0.000 0.504 0.000 0.398 0.000 0.000
Estonian 44000 0.024 0.000 0.236 0.000 0.359 0.000 0.381 0.000 0.000
European 96882 0.027 0.005 0.274 0.020 0.374 0.012 0.329 0.008 0.000
European (USA) 17810 0.023 0.002 0.255 0.005 0.410 0.010 0.311 0.007 0.000
Faroese 311 0.032 0.000 0.309 0.000 0.460 0.000 0.199 0.000 0.000
Finnish (North) 497 0.003 0.000 0.111 0.000 0.585 0.000 0.300 0.000 0.000
Greek 283 0.021 0.000 0.219 0.000 0.442 0.000 0.318 0.000 0.000
Hispanic (USA) 3509 0.021 0.000 0.226 0.006 0.531 0.007 0.223 0.001 0.000
Jewish 250 0.044 0.000 0.252 0.000 0.416 0.000 0.288 0.000 0.000
Jewish (Ashkenazi) 5326 0.023 0.001 0.253 0.010 0.457 0.013 0.264 0.005 0.004
Jewish (Sephardi) 135 0.012 0.000 0.160 0.000 0.522 0.000 0.267 0.000 0.039
Laks (Russian) 46 0.034 0.000 0.300 0.000 0.372 0.000 0.294 0.000 0.000
Macedonian 184 0.027 0.000 0.234 0.000 0.418 0.000 0.321 0.000 0.000
Nanai (Russian) 70 0.108 0.000 0.442 0.000 0.423 0.000 0.028 0.000 0.000
Norwegian 309 0.013 0.000 0.279 0.000 0.395 0.000 0.314 0.000 0.000
Scandinavian 394 0.020 0.000 0.242 0.000 0.450 0.000 0.288 0.000 0.000
Spanish (North) 282 0.018 0.000 0.213 0.000 0.500 0.000 0.269 0.000 0.000
Swedish 185 0.026 0.000 0.269 0.000 0.410 0.000 0.296 0.000 0.000
Middle East
Caspian (Iranian) 73 0.012 0.000 0.194 0.000 0.518 0.000 0.275 0.000 0.000
Fars (Iranian) 180 0.033 0.000 0.298 0.000 0.287 0.000 0.382 0.000 0.000
Iranian 232 0.030 0.015 0.224 0.014 0.414 0.005 0.331 0.023 0.002
Kurd (Iranian) 95 0.077 0.000 0.401 0.000 0.259 0.000 0.264 0.000 0.000
Lure (Iranian) 80 0.127 0.000 0.459 0.000 0.033 0.000 0.381 0.000 0.000
Saudi Arabian 393 0.005 0.001 0.150 0.001 0.603 0.178 0.242 0.176 0.001
Turk (Iranian) 110 0.072 0.000 0.392 0.000 0.214 0.000 0.321 0.000 0.000
Turkish 369 0.027 0.031 0.163 0.186 0.485 0.206 0.325 0.011 0.000
Oceania
Pacific Islander 24 0.000 0.000 0.167 0.000 0.583 0.000 0.250 0.000 0.000
Total 225173 0.042 0.041 0.290 0.079 0.386 0.071 0.287 0.111 0.000
M mean, n number of genotyped subjects, SD standard deviation, PM poor metabolizers, IM intermediate metabolizers, NM normal metabolizers, UM ultrarapid
metabolizers.
aFor references, please see Supplemental Table 3.
bAn SNP combination that could not be assigned to a known allele/phenotype.
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CYP2C19*17, we had only one report describing Ocea-
nians (n= 24)98, which did not identify any PMs.
A limitation is that we were depended on the sensi-
tivity of the tests of the individual studies. For example,
because of overlap in single-nucleotide polymorphisms
in the CYP2D6*10 and *36 and in the CYP2D6*17 and
*40 allele, a slight overestimation or underestimation of
some predicted phenotypes might have been reported in
some studies99.
The inclusion of studies with a small number of par-
ticipants (20–50) could have led to an overestimation or
underestimation of predicted phenotypes in some
populations, but the influence on the mean prevalence
was minimized by weighting the number of genotyped
subjects. We may still have made overestimates or
underestimates where there are few studies for a certain
region/country along with a relatively small number of
studied subjects. Because few studies reporting specific
minority ethnicities met our inclusion criteria, we did not
want to exclude potentially valuable information from
our meta-analysis by setting too-stringent participant
number requirements.
Although we only included studies on homogenous
ethnic groups in this meta-analysis, we are aware of the
limitations of grouping ethnicities based on self-reported
ethnicity. Although ancestry based on genetic information
is more objective than self-reported ethnicity, much of the
research into CYP genotypes has been based on self-
reported ethnicity, while for a few minority populations,
some genetic data were systematically analyzed. In a study
of 103,006 participants with 23 ethnicities, a very high
correspondence was found between self-reported ethni-
city and genetic ancestry100. Only African Americans and
Latino Americans demonstrated a higher degree of
ancestral admixture than self-reported.
Second, although studies of genetic ancestry show there
is a strong linkage between belonging to an ethnic group
and coming from a certain geographical region, ethnicity
is not always the same as geographical region44. Ethnic
groups migrate, and although some ethnicities show
almost no admixture with the local ethnicity even many
years after migration, other ethnicities do show a mixture
of multiple ancestors.
Especially in countries in the Americas, North America,
and Canada, ethnic backgrounds can be diverse and
individual ethnicity is increasingly blurred by admixture,
making self-reported ethnic background or geographical
location less predictive for a correct estimation on a non-
NM predicted phenotype76. The probability estimates per
country (Figs. 2–5) are means of the probability estimates
Fig. 4 CYP2C19 non-normal probability estimates per country. Country (genotyped subjects); non-normal probability estimate in percentage.
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of these different ethnicities and must therefore be
interpreted with caution.
The total means are mean probability estimates of all
the included populations and represent a worldwide
mean probability estimate. Because countries were not
weighted by the number of inhabitants, small countries
with large study populations have a relatively large
influence on the estimated mean. In addition, some
geographical regions were significantly under-
investigated (Africa and the Middle East) and their
predicted phenotype distributions are not adequately
represented in the total estimated means.
Conclusions
In this comprehensive meta-analysis of worldwide
CYP2D6 and CYP2C19 genotype variation,
(>336,000 subjects, 318 reports), we found that the mean
total probability estimates for a non-NM predicted phe-
notype are 36.4% for CYP2D6 and 61.9% for CYP2C19.
The estimates reveal a large geographical variation
(3–61% and 32–80%, respectively). Our results suggest
that more than half of the world population has a non-
normal CYP2D6 and/or CYP2C19 metabolizer predicted
phenotype. Based on the documented probability esti-
mates, pre-emptive pharmacogenetic testing is encour-
aged for every patient who will undergo therapy with a
drug(s) that is metabolized by CYP2D6 and/or CYP2C19
pathways and should be considered in case of treatment
resistance or serious side effects.
Second, many of the studies were not relevant for
clinical practice, because they only investigated a mini-
mum number of allelic variants and thus any phenotype
prediction is unlikely to be accurate. Especially when
estimating the prevalence of the CYP2C19 UM predicted
phenotype, studies in all regions except for East Asia
should genotype on *17 to come to a reliable phenotype
prediction. We therefore recommend that, when allele
frequencies are being studied, a minimum number of
alleles—depending on the geographical region—must be
assessed to be able to predict phenotypes as accurately as
possible101.
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